NASDAQ · SPRB
Spruce Biosciences, Inc.
$45.22-$1.60 (-3.42%)
Spruce Biosciences, Inc.’s quoted price sits in the lower half of its reported 52-week range, 64.95% below the high.
Loading market information…
NASDAQ · NEPH · USD
Stock price, earnings
Quote as of Oct 30, 2026, 06:16 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
Nephros, Inc.’s quoted price sits in the lower half of its reported 52-week range, 48.91% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Nephros, Inc.’s next earnings report is currently expected on Nov 5, 2026, with estimated earnings per share of $0.02. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Nephros, Inc.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Nephros, Inc. is a company that specializes in developing and marketing sophisticated water purification solutions across the United States, catering to both the medical and commercial sectors. Its operations are structured into three primary segments: Water Filtration, Pathogen Detection, and Renal Products. Within its Water Filtration division, Nephros offers advanced ultrafiltration products. These are vital in dialysis centers for eradicating biological contaminants from water and bicarbonate concentrate, and are also deployed in hospitals to prevent infections from waterborne pathogens such as Legionella and Pseudomonas. Their utility extends to military installations, outdoor recreation, commercial establishments, and various other healthcare facilities. The Pathogen Detection segment focuses on developing and distributing real-time water testing systems, which deliver critical, actionable data regarding waterborne pathogens. Furthermore, under its Renal Products segment, the company provides medical devices designed for individuals suffering from renal disease, notably including a second-generation hemodiafiltration system tailored for patients with end-stage renal disease. Additionally, Nephros markets a range of water filters under the Nephros and AETHER brands. These filters are engineered not only to enhance water taste and eliminate odors but also to significantly reduce biofilm, bacteria, and scale accumulation in downstream equipment, serving the food service, hospitality, convenience store, and healthcare industries. Established in 1997, Nephros, Inc. maintains its corporate headquarters in South Orange, New Jersey.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 06:31 PM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| May 9, 2025 |
| $0.05+1,100.0% vs estimate |
| $4.88M+33.56% vs estimate |
| Q4 2024 | Mar 7, 2025 | $0.03+400.0% vs estimate | $3.87M+5.41% vs estimate |
|---|
| Q3 2024 | Nov 7, 2024 | $0.02+199.85% vs estimate | $3.52M-1.46% vs estimate |
|---|
THE ANALYST VIEW
4 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
Percentages compare targets with the quoted price when currencies match. Targets are analyst estimates, not guaranteed outcomes.
Consensus coverage: 1 contributors · Median target $4.00.
Average targets in published notes for each window. These figures use a different sample from the consensus above.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$45.22-$1.60 (-3.42%)
Spruce Biosciences, Inc.’s quoted price sits in the lower half of its reported 52-week range, 64.95% below the high.
$0.46-$0.04 (-7.64%)
Outlook Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 82.06% below the high.
$2.26-$0.41 (-15.23%)
NRx Pharmaceuticals, Inc.’s quoted price sits in the lower half of its reported 52-week range, 55.43% below the high.
$10.29-$0.03 (-0.29%)
ImmuCell Corporation’s quoted price sits in the upper half of its reported 52-week range, 14.96% below the high.
$1.23-$0.07 (-5.38%)
OS Therapies Incorporated’s quoted price sits in the lower half of its reported 52-week range, 46.18% below the high.
$8.17-$0.75 (-8.41%)
Daxor Corporation’s quoted price sits in the lower half of its reported 52-week range, 44.65% below the high.
$0.98-$0.12 (-11.18%)
Werewolf Therapeutics, Inc.’s quoted price sits in the upper half of its reported 52-week range, 31.68% below the high.
$0.54-$0.00 (-0.22%)
HeartBeam, Inc.’s quoted price sits in the lower half of its reported 52-week range, 86.56% below the high.
